Regeneron Pharmaceuticals (REGN) Short-term Investments (2009 - 2026)

Regeneron Pharmaceuticals' Short-term Investments history runs 18 years deep, the most recent figure standing at $5.8 billion for Q1 2026.

• In Q1 2026, Short-term Investments rose 10.11% year-over-year to $5.8 billion; the TTM figure through Mar 2026 stood at $5.8 billion (up 10.11% YoY), while the FY2025 annual figure was $5.5 billion, down 15.9% from the prior year.
• Short-term Investments was $5.8 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $5.5 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $8.1 billion in Q4 2023 to a low of $3.5 billion in Q3 2022.
• Historically, Short-term Investments has averaged $6.0 billion across 5 years, with a median of $5.8 billion in 2026.
• The sharpest annual moves came in 2022 and 2025: Short-term Investments surged 126.87% in 2022, then sank 33.57% in 2025.
• A 5-year view of Short-term Investments shows it stood at $4.6 billion in 2022, then jumped by 75.02% to $8.1 billion in 2023, then declined by 19.6% to $6.5 billion in 2024, then slipped by 15.9% to $5.5 billion in 2025, then gained by 5.54% to $5.8 billion in 2026.
• The last three Short-term Investments figures came in at $5.8 billion (Q1 2026), $5.5 billion (Q4 2025), and $5.9 billion (Q3 2025), per Business Quant data.